PI 3-Kinase Inhibitors
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that play central role in regulation of cell cycle, apoptosis, DNA repair, senescence, angiogenesis, cellular metabolism, and motility. Dysregulated PI3K pathway signaling occurs in one-third of human tumors. The frequent activation of the PI3K pathway in cancer and its crucial role in cell growth and survival has made it an attractive therapeutic target. In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed as anticancer drugs. Idelalisib was the first PI3K inhibitor approved by the US FDA for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. Copanlisib was later approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies. Numerous other PI3K inhibitors are currently in development targeting various combinations of PI3K isoforms. BioVision is proud to offer ~60 PI3K inhibitors for research.
